eli lilly glp 1 market share GLP-1 Analogues Size, & Forecast Report, 2026-2034 GLP-1 Receptor Agonist Market Size

Growing healthcare infrastructure, expanding access to advanced therapies, and rising disposable incomes are enabling more patients to afford GLP-1 treatments

In a phase 2 clinical trial, CagriSema reduced HbA1c by 2.2% (p = 0.075) in comparison with semaglutide 2.4 mg alone [101]

Serious events (like severe pancreatitis or major liver issues) have been rare and similar to placebo so far, but long-term safety is still being monitored in ongoing phase 3 programmes

and glutaredoxin (1.36-fold, p=0.024), a thioltransferase thought to provide an antioxidant-associated protective effect against coronary atherosclerosis

GLP-1 medications reduce thirst signaling alongside hunger signaling, so many patients are already running mildly dehydrated before adding a diuretic on top

GLP-1 receptor agonists mechanism of action mimics the naturally occurring GLP-1 in the body, which results in improved blood sugar control